{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:09:39Z","timestamp":1780657779647,"version":"3.54.1"},"reference-count":14,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>Context Tumor necrosis factor-alpha (TNF-\u03b1) inhibitor therapy plays a pivotal role in the management of moderate to severe inflammatory bowel disease. Because of the role of TNF-\u03b1 in the host defenses, anti-TNF therapy has been associated with an increase the risks of granulomatous infections. Objective To report the first case of adalimumab-associated invasive histoplasmosis presenting as an acute hepatitis-like syndrome and febrile pneumonitis in a patient with Crohn\u2019s disease. Method Case report of a patient with progressive histoplasmosis confirmed by percutaneous fine needle aspiration biopsy lung and urine Histoplasma antigen. Results We present the case of a young man with CD who developed pneumonia and acute hepatitis-like features caused by Histoplasma capsulatum infection during adalimumab therapy. To the best of our knowledge, this acute hepatitis-like manifestation has never been reported as a presentation of the histoplasmosis in patients with Crohn\u2019s disease. Conclusions This case underscores the potential risk for serious infection that may arise in this setting and should alert clinicians to the need to consider the histoplasmosis diagnosis in patients presenting with acute hepatitis-like syndrome associated with prolonged febrile illness or pneumonitis during therapy with anti-TNF-\u03b1 antibodies.<\/jats:p>","DOI":"10.1590\/s0004-28032014000100015","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T08:40:15Z","timestamp":1404290415000},"page":"73-76","source":"Crossref","is-referenced-by-count":10,"title":["HEPATITIS AND PNEUMONITIS DURIN ADALIMUMAB THERAPY IN CROHN\u2019 DISEASE: mind the histoplasmosis!"],"prefix":"10.1590","volume":"51","author":[{"given":"Bruno do Valle","family":"PINHEIRO","sequence":"first","affiliation":[{"name":"Hospital da Universidade Federal de Juiz de Fora, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ureo de Almeida","family":"DELGADO","sequence":"additional","affiliation":[{"name":"Hospital Santa Casa, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Maria Fonseca","family":"CHEBLI","sequence":"additional","affiliation":[{"name":"Hospital da Universidade Federal de Juiz de Fora>, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ibd.21378","article-title":"Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series","volume":"17","author":"Dotson JL","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage CA","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-2008-1063854","article-title":"Pulmonary histoplasmosis","volume":"29","author":"Hage CA","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/CMR.00027-06","article-title":"Histoplasmosis: a clinical and laboratory update","volume":"20","author":"Kauffman CA","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/QCO.0b013e328306eb8d","article-title":"Diagnosis of histoplasmosis in immunosuppressed patients","volume":"21","author":"Kauffman CA","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1665-2681(19)32064-2","article-title":"Hepatobiliary diseases in patients with human immunodeficiency virus (HIV) treated with non highly active anti-retroviral therapy: frequency and clinical manifestations","volume":"4","author":"Lizardi-Cervera J","year":"2005","journal-title":"Ann Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrgastro.2013.31","article-title":"First-line therapy in adult Crohn\u2019s disease: who should receive anti-TNF agents?","volume":"10","author":"Peyrin-Biroulet L","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1086\/648421","article-title":"Diagnosis of acute pulmonary histoplasmosis by antigen detection","volume":"49","author":"Swartzentruber S","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor- \u03b1 blockade therapy","volume":"83","author":"Tsiodras S","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis RS","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1517\/14712598.6.11.1207","article-title":"Improvements in diagnosis of histoplasmosis","volume":"6","author":"Wheat LJ","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-97-5-680","article-title":"The diagnostic laboratory tests for histoplasmosis: analysis of experience in a large urban outbreak","volume":"97","author":"Wheat LJ","year":"1982","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","article-title":"Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy","volume":"167","author":"Wood KL","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ddr.20481","article-title":"Azathioprine in ulcerative colitis: Why, when, how and how long to use it","volume":"72","author":"Ribeiro TCR","year":"2011","journal-title":"Drug Development Research"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v51n1\/0004-2803-ag-51-01-00073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T09:42:05Z","timestamp":1565602925000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032014000100073&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0004-28032014000100073"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032014000100015","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}